protein tyrosine phosphatase receptor type QGenealiases: DFNA73 · DFNB84 · DFNB84A · PTPGMC1 · R-PTP-Q
Q-omics provides the consensus-scored PTPRQ profile across patient tissues and cancer cell-line models. PTPRQ expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PTPRQ is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PTPRQ RNA expression shows 13,159 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where PTPRQ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPRQ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPRQ survival associations across molecular data types. PTPRQ RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPRQ RNA expression–survival associations across cancer types. High PTPRQ expression shows unfavorable associations in KIRP, KIRC, BLCA and KICH, but favorable associations in LUAD and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PTPRQ RNA expression.
This table summarizes PTPRQ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PTPRQ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPRQ shows lower tumor expression in KIRC, THCA, LUAD, LUSC, BRCA and KICH. The KIRC box plot shows higher PTPRQ RNA expression in normal versus tumor tissue (log2 FC = −0.549, t-test p < 0.001).
This table shows molecular features associated with PTPRQ in patient tissues and cancer cell lines. In patient samples, PTPRQ shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPRQ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
